Innovo Therapeutics
PrivateLast Round
Series C
Dec 1, 2025
Est. Valuation
$77M
Total Funding Raised
$48.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Innovo Therapeutics operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series C round in December 2025.
Innovo Therapeutics is a biotechnology company that develops small molecule therapies for inflammation, fibrosis, and oncology using its proprietary AI-augmented drug discovery platform, DeepZema®.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Innovo Therapeutics Comparables
Compare Innovo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PharmCADD Co., Ltd. | 86% | |
| Standigm | 84% | |
| HITS Inc. | 83% |
For institutional investors. Book with your work email.
Innovo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Dec 1, 2025 | ||||
| Series B | Nov 1, 2021 | ||||
| Series A | Dec 1, 2019 |
For institutional investors. Book with your work email.
Innovo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Investment | Series A, Series B |
| Company K Partners | Series B |
| Mirae Asset Capital | Series A, Series B |
| IMM Investment | Series B |
| Mirae Asset Venture Investment | Series A, Series B |
| Tigris Investment | Series B |
| Atinum Investment | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 24, 2026
Grew 100% QoQ, from 3 to 6 employees.
- Jul 28, 2026
Monthly visitors increased 166% MoM, reaching 4.5K.
For institutional investors. Book with your work email.
Innovo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Innovo Therapeutics's valuation, stock price, and market status.
Is Innovo Therapeutics a public or private company?
Innovo Therapeutics is a private company.
What is the current stock price of Innovo Therapeutics?
Innovo Therapeutics is a private company, so its shares have no public market price. Caplight tracks Innovo Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Innovo Therapeutics worth (valuation)?
Innovo Therapeutics's valuation is estimated at $77.0M based on funding round data.
Can I buy Innovo Therapeutics stock?
Innovo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Innovo Therapeutics's last funding round?
Innovo Therapeutics's most recent funding round was Series C on December 1, 2025.
Who are the main investors in Innovo Therapeutics?
Key investors in Innovo Therapeutics include SV Investment, Company K Partners, Mirae Asset Capital, IMM Investment, Mirae Asset Venture Investment.
Will Innovo Therapeutics IPO soon?
No public IPO plans have been announced for Innovo Therapeutics.
How can I track Innovo Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Innovo Therapeutics's shares on secondary markets.